血液科
臨床結果
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. （開啟新視窗）
來源: Lancet Haematol 2018;5(3):e117-e126.
檢索: PubMed 29396092
DOI碼: 10.1016/S2352-3026(18)30016-4
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. （開啟新視窗）
來源: Cancer 2013;119(1):107-14.
檢索: PubMed 22744794
DOI碼: 10.1002/cncr.27686